| A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4 |
Ongoing |
Everolimus/ Afinitor |
3 |
CRAD001T2302 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy |
Completed |
Everolimus |
3 |
CRAD001N2301 |
King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma (EVERMORE). |
Ongoing |
Everolimus |
2 |
CRAD001LIC01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A 24 month, randomized, controlled, study to evalute the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus in recipients of living donor liver transplants. |
Ongoing |
Everolimus / reduced tacrolimus / Tacrolimus |
3 |
CRAD001H2307 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly. |
Ongoing |
Pasireotide |
3 |
CSOM230C2402 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). |
Ongoing |
Ruxolitinib |
3b |
CINC424A2401 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) |
Ongoing |
Deferasirox / Defearisox new formula |
2 |
CICL670F2201 |
King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Daily practice treatment and Influence of Visanne on the patient Assessment of quality of life parameters |
Completed |
Visanne |
4 |
VS1101 |
King Khalid University Hospital (Riyadh), Soliman Fakeeh Hospital (Jeddah) |
| An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting |
Completed |
Sitagliptin |
4 |
MK0431-263 |
Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh) |
| A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin |
Completed |
BIAsp 30 / Metformin |
4 |
BIAsp 3968 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Forces Hospital (Al-Hada) |
